Arterial and Venous Thrombosis Complicated in COVID-19: A Retrospective Single Center Analysis in Japan

Seiya Oba 1, Tadashi Hosoya 1*, Miki Amamiya 2, Takahiro Mitsumura 3, Daisuke Kawata 1, Hirokazu Sasaki 1, Mari Kamiya 1, Akio Yamamoto 1, Takahiro Ando 3, Sho Shimada 1, Tsuyoshi Shirai 3, Tsukasa Okamoto 3, Tomoya Tateishi 3, Akira Endo 4, Junichi Aiboshi 4, Nobuyuki Nosaka 5, Hideo Yamanouchi 2, Toyomu Ugawa 5, Eiki Nagaoka 6, Keiji Oi 6, Susumu Tao 1, Yasuhirou Maejima 2, Yukie Tanaka 7, Kousuke Tanimoto 7,8, Hiroaki Takeuchi 9, Shuji Tohda 10, Akihito Hirakawa 11, Tetsuo Sasano 2, Hirokuni Arai 1, Yasuhiro Otomo 4, Yasunari Miyazaki 3 and Shinsuke Yasuda 1*

Background: Thrombosis is a characteristic complication in coronavirus disease 2019 (COVID-19). Since coagulopathy has been observed over the entire clinical course, thrombosis might be a clue to understanding the specific pathology in COVID-19. Currently, there is limited epidemiological data of COVID-19-associated thrombosis in the Japanese population and none regarding variant strains of SARS-CoV-2. Here, we elucidate the risk factors and the pattern of thrombosis in COVID-19 patients.

Methods: The patients consecutively admitted to Tokyo Medical and Dental University Hospital with COVID-19 were retrospectively analyzed. SARS-CoV-2 variants of concern/interest (VOC/VOI) carrying the spike protein mutants E484K, N501Y, or L452R were identified by PCR-based analysis. All thrombotic events were diagnosed by clinical symptoms, ultrasonography, and/or radiological tests.

Results: Among the 516 patients, 32 patients experienced 42 thromboembolic events. Advanced age, severe respiratory conditions, and several abnormal laboratory markers were associated with the development of thrombosis. While thrombotic events occurred in 13% of the patients with a severe respiratory condition, those
INTRODUCTION

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has quickly spread worldwide and has yet to be brought under control. Although the major cause of death is respiratory failure, a wide range of unique complications has been observed in COVID-19 patients, including macrophage activating syndrome, multisystem inflammatory syndrome in children (MIS-C), and thrombosis (1, 2). Various studies have revealed incidences of deep vein thromboses and pulmonary embolisms in patients with severe disease, especially in patients admitted to the intensive care unit (ICU) (3–5).

Coagulopathy is a particular pathology observed with COVID-19 (6, 7). Various types of innate immune activation, including cytokine release, endothelial cell activation, and enhanced neutrophil extracellular traps, have been seen simultaneously in patients with thrombotic complications, indicating that the immunothrombosis might play a key role in the development of thrombosis in COVID-19 (1, 8–10). D-dimer is known to be markedly elevated over the clinical course of COVID-19 and is a risk factor for poor prognosis (2, 11, 12). Microembolisms in the pulmonary capillaries could impair oxygenation and induce so-called “silent hypoxia,” which was seen in the early stages of COVID-19 as a discrepancy of oxygen and carbon dioxide levels (12).

The worldwide pandemic is still ongoing and has even expanded in some countries with emerging SARS-CoV-2 variants of concern (VOC) and variant of interest (VOI), such as alpha variant (B.1.1.7), beta variant (B.1.351), gamma variant (P.1), delta variant (B.1.617.2), and R.1 variant (13). Since these variants carry various mutants, the properties of virus would be changed in terms of transmissibility, disease severity, the performance of vaccines, and complications (14). The clinical characteristics of COVID-19 caused by VOC/VOI have not yet been fully elucidated, including the incidence of thrombosis.

So far, there is limited evidence about the incidence of thrombosis and the association of biomarkers in Japanese population, except a few (15–18). The objective of the current study was to identify the risk factors for the development of thrombosis. In this retrospective study, we surveyed the clinical characteristics of thromboses in patients hospitalized for COVID-19 from the early phase of the pandemic to the recent cases caused by VOC/VOI in Japan. Here, we report the incidence of venous and arterial thrombosis, the pattern of sequential changes in biomarkers before the development of thrombosis, the incidence of thrombosis, and the proportion of VOC/VOI in a relatively large number of the patients at a single center.

MATERIALS AND METHODS

Study Design/Setting

This single-center retrospective observational study included all patients with confirmed COVID-19 who were admitted to Tokyo Medical and Dental University (TMDU) hospital, a Japanese tertiary emergency hospital in an urban setting. The diagnosis of COVID-19 was made by detecting N gene of SARS-CoV-2 described previously (19). Briefly, clinical samples were obtained from oropharyngeal swabs and were analyzed with real-time reverse-transcription PCR (RT-PCR) using the method established in the National Institute of infectious disease in Japan (20), or 2019 Novel Coronavirus Detection Kit (Shimadzu Corporation, Kyoto, Japan). As the proportion of SARS-CoV-2 variants carrying either N501Y, E484K, and L452R mutations was expanded, RT-PCR was performed using VirSNiP SARS-CoV-2
(TIB Molbiol, Berlin, Germany). The mutation types were determined by the melting temperature.

This study protocol was approved by the ethics committees of TMDU. Reference ID was M2020-027.

**Data Collection and Definition**

All the data, namely viral strains, demographics, disease severity, comorbidities, laboratory data, treatment, and outcomes were collected from electronic medical records.

Disease severity was measured on admission and at times of the most severe clinical condition. Based on the "guideline of the medical treatment of the noble coronavirus" presented by Japanese ministry of Health, Labor, and Welfare (21), disease severity was defined as follows: mild, for patients who do not need oxygen therapy; moderate, for patients who need oxygen of equal or <5 L/min; and severe, for patients who need oxygen of more than 5 L/min or mechanical ventilation.

Anticoagulation therapy was considered in the patients with severe disease, elevated D-dimer (>5 µg/mL), and/or in those who received baricitinib. Unfractionated heparin at therapeutic doses was defined as the dose determined in reference to the activated partial thromboplastin time (APTT). Unfractionated heparin at prophylactic doses was defined as a fixed dose (≤10,000 U/day), regardless of the APTT.

Acute myocardial infarctions (AMI), ST-elevation myocardial infarction and non-ST-elevation myocardial infarction, were diagnosed based on dynamic changes in cardiac enzyme levels, electrocardiogram findings, and ultrasound cardiology findings. Cerebral infarction was diagnosed based on symptoms and magnetic resonance imaging findings. Other arterial thromboses were diagnosed by contrast-enhanced CT scanning. Venous thromboembolism was diagnosed by contrast-enhanced computed tomography scanning, ultrasonography, autopsy, or clinically evident cases (i.e., the coincidence of rapid deterioration of the respiratory condition and marked elevation of D-dimer levels). Major bleeding was defined according to the International Society on Thrombosis and Haemostasis as overt bleeding which includes the following: fatal bleeding, symptomatic bleeding in a critical area or organ (i.e., intracranial, intraspinal, intraocular, retroperitoneal, intraarticular, pericardial, intramuscular with compartment syndrome), bleeding causing a fall in hemoglobin level of 20 g/l or more, or leading to transfusion of two or more units of whole blood or red cells (22).

**Statistical Analysis**

We compared the distributions of continuous and categorical variables between the two groups using the Student's t-test (or Mann–Whitney U-test) and Chi-squared test (or Fisher's exact test), respectively. Univariate and multivariate logistic regression analyses were used to examine the impacts of the following variables on the development of arterial thrombosis: older age (≥65 vs. <65 years old), severity on admission (severe vs. mild/moderate), D-dimer (≥0.71 vs. <0.71 µg/mL), CRP (≥3.95 mg/dL vs. <3.95 mg/dL), and ferritin (≥434 vs. <434 ng/mL). Variables included in the multivariate logistic model were selected with the known risk factors (older age, disease severity, and D-dimer) (23–25), and the biomarker of inflammation (CRP) and macrophage activating syndrome (ferritin) were selected as the variables of interest for this study. The median values in 516 patients we analyzed were chosen as cutoff points for the D-dimer, CRP, and ferritin. The odds ratio (OR) including 95% confidence interval (CI) were estimated. Statistical significance was defined as p < 0.05. All statistical analyses were performed using IBM SPSS, version 27 (IBM, Armonk, NY, USA).

**RESULTS**

**Clinical Characteristics of Patients With and Without Thrombosis**

We analyzed 516 consecutive patients from April 1, 2020, to July 31, 2020. The mean age of the patients was 57.2 ± 17.5 years old, 358 patients (69%) were men, and the mean body mass index (BMI) was 24.3 ± 4.9 kg/m². Disease severity on admission was mild in 279 (54%), moderate in 128 (25%), and severe in 109 (21%) patients (Supplementary Table 1).

Of those, 32 patients (5.3%) experienced 42 thromboembolic events. Multiorgan infarctions were identified simultaneously in five patients. The mean age was significantly older in patients with thrombosis (66.9 vs. 56.1 years). In terms of the respiratory condition on admission, patients with thrombosis comprised a higher proportion of severe category than those without (44 vs. 20%). While thrombotic events occurred in 13% of the patients with a severe respiratory condition, these events still occurred in 2.5% of the patients who did not require oxygen supply (Table 1).

Among the underlying comorbidities, impaired renal function (eGFR < 60 ml/min/1.73 m²) was more frequently observed in thrombotic cases (50 vs. 28%). Patients experiencing thrombotic events had significantly higher white blood cell counts and higher levels of C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, D-dimer, fibrinogen, and fibrinogen degradation products (FDP), prolonged prothrombin time (PT), and lower lymphocyte counts and hemoglobin levels than those without thrombotic events on admission (Table 1).

Multivariate logistic regression models revealed that elevated D-dimer levels over 0.71 µg/mL (adjusted odds ratio 9.39, 95% confidence interval 2.08–42.3) and ferritin levels over 434 ng/mL (adjusted odds ratio 3.11, 95% confidence interval 1.06–9.17) were independent predictive factors for the thrombosis (Table 2).

**Arterial vs. Venous Thrombosis**

As reported previously in COVID-19 associated thrombosis (26, 27), the unique patterns of thromboses were observed in our study (Figure 1, Supplementary Table 2). Of the 42 thrombotic events, 20 (48%) events were arterial thrombosis. Among the arterial thrombotic events, acute coronary syndrome was the most frequently observed in eight and cerebral infarction was observed in four. A total of five atypical arterial thrombotic cases were diagnosed: two cases of cooccurrence of myocardial infarction and cardiac ventricular thrombosis; a cooccurrence of splenic and renal infarction; and of note, floating thrombus in the ascending aorta was detected in two
### TABLE 1 | Clinical characteristics of the patients complicated with or without thrombosis in the cohort.

|                      | All patients $(N = 516)$ | Thrombosis $(N = 32)$ | Non thrombosis $(N = 484)$ | $p$-value* |
|----------------------|--------------------------|-----------------------|-----------------------------|------------|
| **Baseline characteristics** |                          |                       |                             |            |
| Age, mean (SD)       | 57.2 (17.5)              | 66.9 (12%)            | 56.6 (17.6)                 | <0.001     |
| $\geq$65 years, n (%)| 198 (38%)                | 22 (69%)              | 176 (36%)                   | <0.001     |
| Male gender, n (%)   | 358 (69%)                | 25 (78%)              | 333 (69%)                   | 0.33       |
| Body mass index (kg/m$^2$), mean (SD) | 24.3 (4.9) | 24.3 (4.0) | 24.3 (5.0) | 0.99 |
| $\geq$30 kg/m$^2$, n (%) | 53 (10%)      | 2 (6.3%)              | 51 (11%)                    | 0.56       |
| Current smoker, n (%)| 87                       | 2 (6.3%)              | 85 (18%)                    | 0.13       |
| Severity on admission, n (%) |                        |                       |                             | <0.001     |
| Mild                 | 279 (54%)                | 7 (21.9%)             | 272 (56%)                   |            |
| Moderate             | 128 (25%)                | 11 (34%)              | 117 (24%)                   |            |
| Severe               | 109 (21%)                | 14 (44%)              | 95 (20%)                    |            |
| **Comorbidities**    |                          |                       |                             |            |
| Diabetes mellitus, n (%) | 112 (22%)                | 5 (16%)               | 107 (22%)                   | 0.39       |
| Hypertension, n (%)  | 173 (34%)                | 9 (28%)               | 164 (34%)                   | 0.5        |
| Hyperlipidemia, n (%)| 82 (16%)                 | 3 (9.4%)              | 79 (16%)                    | 0.3        |
| COPD, n (%)          | 14 (2.7%)                | 1 (3.1%)              | 13 (2.7%)                   | 0.60       |
| Asthma, n (%)        | 37 (8.1%)                | 0 (0%)                | 37 (8.1%)                   | 0.16       |
| eGFR < 60 ml/min/1.73m$^2$, n (%) | 149 (29%) | 16 (50%) | 133 (28%) | 0.006 |
| History of coronary artery disease, n (%) | 19 (3.7%) | 2 (6.3%) | 17 (3.5%) | 0.33 |
| History of cerebral infarction, n (%) | 24 (4.7%) | 4 (13%) | 20 (4.1%) | 0.05 |
| History of malignancy, n (%) | 70 (14%) | 6 (19%) | 64 (13%) | 0.42 |
| Active malignancy, n (%) | 14 (2.7%) | 1 (3.1%) | 13 (2.7%) | 0.60 |
| Autoimmune disease, n (%) | 30 (6.2%) | 4 (13%) | 26 (5.4%) | 0.11 |
| **Laboratory data on admission** |                          |                       |                             |            |
| White blood cell count ($\times 10^3$/$\mu$L), median (IQR) | 5.4 (4.1–7.3) | 9.0 (4.1–7.2) | 5.4 (5.4–9.9) | 0.003 |
| Lymphocyte count ($\mu$L), median (IQR) | 968 (651–1,315) | 867 (686–1,326) | 987 (443–779) | <0.001 |
| Hemoglobin (g/dL), median (IQR) | 14.3 (12.9–15.4) | 13.1 (12.9–15.5) | 14.3 (11.6–14.7) | 0.01 |
| Platelet count ($\times 10^3$/$\mu$L), median (IQR) | 18.8 (15.6–24.0) | 20.7 (15.7–24.0) | 19.2 (13.3–25.6) | 0.42 |
| CRP (mg/dL), median (IQR) | 3.95 (0.88–9.6) | 12.6 (0.78–8.72) | 3.59 (7.58–16.0) | <0.001 |
| LDH (U/L), median (IQR) | 292 (213–393) | 494 (212–388) | 284 (320–474) | <0.001 |
| Ferritin (ng/mL), median (IQR) | 434 (208–918) | 1,124 (193–848) | 403 (508–1335) | <0.001 |
| Creatinine (mg/dL), median (IQR) | 0.64 (0.66–1.03) | 1.91 (0.65–1.00) | 0.83 (0.69–1.28) | 0.11 |
| PT (second), median (IQR) | 11.1 (10.5–12.0) | 12.9 (10.4–11.9) | 11.1 (11.0–14.1) | <0.001 |
| APTT (second), median (IQR) | 32.0 (29.3–35.3) | 35.5 (29.3–35.1) | 31.9 (29.1–38.5) | 0.18 |
| D-dimer ($\mu$g/mL), median (IQR) | 0.71 (0.50–1.60) | 11.6 (0.5–1.5) | 0.67 (1.2–11.3) | <0.001 |
| Fibrinogen (mg/dL), median (IQR) | 480 (376–565) | 570 (376–558) | 471 (465–699) | <0.001 |
| FDP ($\mu$g/mL), median (IQR) | 3.35 (2.5–5.7) | 36.0 (2.5–5.3) | 3.2 (3.5–20.0) | <0.001 |

*Chi-squared test or Fisher’s exact test for categorical variables, student’s t-test for age and Body mass index and Mann–Whitney U test for laboratory data. Statistically significant $p < 0.05$ values are in bold. SD, standard deviation; IQR, Interquartile range; COPD, Chronic Obstructive Pulmonary Disease; CRP, C reactive protein; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrinogen degradation products.

cases, resulting in the infarction of brain and spleen, or left extremity, respectively (Supplementary Figure 1). Out of 22 (52%) venous thrombotic events, 11 were complicated with pulmonary thrombosis without deep vein thrombosis (DVT), while four were identified as the cooccurrence of DVT and pulmonary embolism. The other three were complicated DVT alone. No cooccurrence of arterial and venous thrombosis was observed.

There was no difference in the clinical characteristics between patients with arterial or venous thrombotic events, except for the peak D-dimer levels (Table 3). The median durations from the disease onset to the development of an arterial or a venous thrombotic event were 13 and 16 days, respectively. The clinical significances were variable depending on the disease conditions (Supplementary Table 2). The deterioration of respiratory condition was observed in nine cases after the development of thrombosis. Among the 32 cases, 21 received escalation of anticoagulation strategy, whereas the others did not, based on their clinical conditions such as bleeding complications or poor prognosis.
TABLE 2 | Univariate analysis and multivariate logistic regression analysis adjusted for the variables.

| Variables | Univariate analysis | Multivariate analysis |
|-----------|---------------------|-----------------------|
|           | OR  | 95% CI  | p-value | OR  | 95% CI  | p-value |
| Older age | 3.82 | 1.62–8.99 | 0.002 | 1.64 | 0.70–3.82 | 0.25 |
| Severity  | 3.36 | 1.54–7.34 | <0.001 | 1.23 | 0.52–2.87 | 0.64 |
| D-dimer   | 10.7 | 3.22–35.7 | <0.001 | 9.39 | 2.08–42.3 | 0.004 |
| CRP       | 4.71 | 1.90–11.6 | <0.001 | 1.91 | 0.64–5.69 | 0.25 |
| Ferritin  | 5.23 | 1.96–14.0 | <0.001 | 3.11 | 1.06–9.17 | 0.04 |

Statistically significant p < 0.05 values are in bold. CI, confidence interval.

FIGURE 1 | Distribution of the thrombotic events. Pie chart represents the proportion of 42 thrombotic events complicated in 32 patients.

The proportion of 42 thrombotic events

- Pulmonary thromboembolism: 15
- Deep vein thrombosis: 7
- Acute coronary syndrome: 8
- Intracardiac thrombosis: 2
- Cerebral infarction: 4
- Aortic thrombosis: 2
- Splenic infarction: 2
- Peripheral arterial obstruction: 1
- Renal infarction: 1
- Total events: 42

Arterial thrombosis: 48%  Venous thrombosis: 52%

Treatments and Outcomes
Clinical courses of the patients are summarized in Table 4. Regarding the treatments in those with or without thrombosis, glucocorticoid (75 vs. 52%), tocilizumab (28 vs. 6.0%), and unfractionated heparin at therapeutic doses (47 vs. 7.9%) were used more frequently in patients complicated with thrombosis. Thirteen out of the 32 patients with thrombosis developed thrombosis even under prophylactic or therapeutic anticoagulation therapy, indicating that thrombotic events could not be prevented by anticoagulation in some patients. Among the 13 cases, seven were arterial thrombosis and six were venous.

In patients with thrombosis, the percentages of patients who needed oxygen therapy (91 vs. 60%), mechanical ventilation (60 vs. 24%), the rate of mortality (25 vs. 6.0%), and bleeding complications (22 vs. 1.7%) were significantly higher than in those without.

Clinical Course and Changes in Coagulation Marker Over Time
To explore the underlying mechanism of thrombosis in COVID-19, we analyzed the sequential changes in the balance of coagulation and fibrinolysis biomarkers and inflammatory status in the 32 patients (Figure 2). In most of the thrombotic patients, FDP and D-dimer levels began to be elevated several days before the occurrence of thrombosis. When the respiratory condition was sequentially evaluated, we found that thrombosis occurred during exacerbation in seven cases, sustaining in 16 cases, and improvement in nine cases. Notably, in the last group of cases, the temporal discrepancy of inflammation and coagulopathy was apparent, namely, inflammation peaked 1 week before the onset of thrombosis, whereas FDP and D-dimer levels were elevated simultaneously with the onset of thromboses (Supplementary Figure 2).
TABLE 3 | Clinical course of the patients complicated with arterial thrombosis or venous thromboembolism.

|                          | Arterial thrombosis (N = 14) | Venous thromboembolism (N = 18) | p-value |
|--------------------------|------------------------------|---------------------------------|---------|
| **Baseline characteristics** |                              |                                 |         |
| Age, mean (SD)           | 70 (10.6)                    | 64.4 (12.6)                     | 0.18    |
| Male gender, n (%)       | 12 (86%)                     | 13 (72%)                        | 0.43    |
| Body mass index (kg/m²), mean (SD) | 26.4 (3.1)               | 22.9 (3.9)                      | 0.15    |
| ICU admission, n (%)     | 5 (36%)                      | 8 (62%)                         | 0.62    |
| Severity on admission, n (%) |                          |                                 |         |
| Mild                     | 4 (29%)                      | 3 (17%)                         | 0.68    |
| Moderate                 | 4 (29%)                      | 6 (33%)                         |         |
| Severe                   | 6 (43%)                      | 9 (50%)                         |         |
| Days from onset to thrombosis, median (IQR) | 13 (6–20)             | 16 (14–18)                      | 0.15    |
| **Comorbidities**        |                              |                                 |         |
| Diabetes mellitus, n (%) | 2 (14%)                      | 3 (16.7%)                       | 1.00    |
| Hypertension, n (%)      | 4 (29%)                      | 5 (28%)                         | 1.00    |
| Hyperlipidemia, n (%)    | 1 (7.1%)                     | 2 (11%)                         |         |
| COPD, n (%)              | 1 (7.1%)                     | 0 (0%)                          | 0.44    |
| Asthma, n (%)            | 0 (0%)                       | 0 (0%)                          |         |
| eGFR < 60 ml/min/1.73 m², n (%) | 9 (64%)                 | 7 (39%)                         | 0.15    |
| History of coronary artery disease, n (%) | 2 (15%)                  | 0 (0%)                          | 0.18    |
| History of cerebral infarction, n (%) | 1 (6.6%)                  | 3 (21%)                         | 0.30    |
| History of malignancy, n (%) | 2 (14%)                   | 4 (22%)                         | 0.67    |
| Active malignancy, n (%) | 0 (0%)                       | 1 (5.6%)                        | 1.00    |
| Autoimmune disease, n (%) | 2 (11%)                    | 2 (11%)                         | 1.00    |
| **Laboratory data at the onset of thrombosis** |                          |                                 |         |
| White blood cell count (×10³/µL), median (IQR) | 7.4 (5.5–10.9) | 8.6 (6.7–11.3) | 0.46    |
| Hemoglobin (g/dL), median (IQR) | 12.3 (10.9–14.1) | 12.7 (10.0–13.9) | 0.78    |
| Platelet count (×10⁹/µL), median (IQR) | 24.5 (9.0–31.1) | 26.9 (13.0–33.6) | 0.61    |
| CRP (mg/dL), median (IQR) | 1.67 (0.62–6.16)            | 7.20 (1.13–16.1)                | 0.10    |
| Ferritin (ng/mL), median (IQR) | 392 (229–932)          | 1,054 (592–1,610)               | 0.06    |
| D-dimer (µg/mL), median (IQR) | 5.0 (3.26–13.2)       | 16.8 (9.2–41.3)                 | **0.01**|
| Fibrinogen (mg/dL), median (IQR) | 303 (155–510)          | 378 (253–585)                   | 0.47    |
| FDP (µg/mL), median (IQR) | 8.8 (6.6–14.8)             | 24.7 (7.1–42.6)                 | 0.15    |
| PT (second), median (IQR) | 11.8 (10.6–13.3)           | 13.2 (11.7–16.0)                | 0.12    |
| APTT (second), median (IQR) | 35.0 (27.1–39.4)       | 38.6 (28.5–48.4)                | 0.21    |
| **Outcomes**             |                              |                                 |         |
| Death, n (%)             | 2 (14%)                      | 6 (33%)                         | 0.41    |

Statistically significant p < 0.05 values are in bold. SD, Standard Deviation; IQR, Interquartile range; COPD, Chronic Obstructive Pulmonary Disease; CRP, C reactive protein; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrinogen degradation products.

**Thrombosis in COVID-19 Caused by SARS-CoV-2 VOC/VOI or Non-COV/VOI**

As we have reported, the ratio of VOC/VOI carrying N501Y or E484K mutation rapidly increased in our hospital during the observation period, and the proportion of VOC/VOI reached 100% by the end of April in 2021 (Figure 3A). Unexpectedly, the incidence of thrombosis showed decreased trend from March in 2021 (Figure 3B). Therefore, we compared the patient's characteristics of COVID-19 caused by SARS-CoV-2 VOC/VOI to those by non-VOC/VOI. We found that the proportion of severe category was similar (20 vs. 22%), whereas the incidence of thrombosis was less frequent in the COVID-19 caused by VOC/VOI than the others (1.3 vs. 8.2%). In addition, the younger age and high frequency of anticoagulation therapy at therapeutic doses were also observed in the patients with COVID-19 caused by VOC/VOI (Table 5).

**DISCUSSION**

Our study revealed that thrombotic complications developed more frequently in patients with a severe respiratory disease on admission and were associated with death, consistent with the previous findings in the Japanese population (16). Additionally, elevated D-dimer and ferritin levels on admission were the risk factors for the development of thrombosis. Arterial and venous thrombotic complications occurred at similar rates.
TABLE 4 | Clinical course of the first cohort patients complicated with or without thrombosis.

|                        | All patients | Thrombosis | Non-Thrombosis | p-value |
|------------------------|--------------|------------|----------------|---------|
|                        | (N = 516)    | (N = 32)   | (N = 484)      |         |
| **Non-Pharmacological intervention** |              |            |                |         |
| ICU admission, n (%)   | 109 (21%)    | 13 (41%)   | 96 (20%)       | 0.005   |
| Oxygen therapy, n (%)  | 316 (61%)    | 29 (91%)   | 289 (60%)      | <0.001  |
| Mechanical ventilation, n (%) | 136 (26%)   | 19 (60%)   | 117 (24%)      | <0.001  |
| Renal replacement therapy, n (%) | 33 (6.4%)   | 5 (16%)    | 28 (5.8%)      | 0.045   |
| **Maximum severity, n (%)** |              |            |                |         |
| Mild                   | 186 (36%)    | 2 (6.3%)   | 184 (38%)      |         |
| Moderate               | 183 (36%)    | 8 (25%)    | 175 (36%)      |         |
| Severe                 | 147 (28%)    | 22 (69%)   | 125 (26%)      |         |
| **Laboratory data at the peak severity** |              |            |                |         |
| CRP (mg/dL), median (IQR) | 6.22 (2.08–13.9) | 14.6 (10.3–21.8) | 5.84 (1.95–12.6) | <0.001 |
| D-dimer (µg/ml), median (IQR) | 2.01 (0.76–6.1) | 16.9 (7.21–48.7) | 1.80 (0.70–4.42) | <0.001 |
| **Treatment**          |              |            |                |         |
| Glucocorticoid therapy, n (%) | 274 (53%) | 24 (75%)  | 250 (62%)      | 0.010   |
| Tocilizumab, n (%)     | 38 (7.4%)    | 9 (28%)    | 29 (6%)        | <0.001  |
| DOAC, n (%)            | 26 (5.0%)    | 10 (31%)   | 16 (3.3%)      | <0.001  |
| Prophylactic anticoagulation dose, n (%) | 131 (25%) | 11 (34%)  | 120 (25%)      | 0.23    |
| Therapeutic anticoagulation dose, n (%) | 53 (10%) | 15 (47%)  | 38 (7.9%)      | <0.001  |
| **Outcomes**           |              |            |                |         |
| Major bleeding, n (%)  | 15 (2.9%)    | 7 (22%)    | 8 (1.7%)       | <0.001  |
| Death, n (%)           | 37 (7.2%)    | 8 (25%)    | 29 (6.0%)      | <0.001  |
| Length of hospitalization (days) | 16.5 (8–20) | 25.5 (16–36) | 15.5 (8–19)   | <0.001  |

Statistically significant p < 0.05 values are in bold. IQR, interquartile range; ICU, intensive care unit; CRP, C-reactive protein; DOAC, direct oral anticoagulant.

FIGURE 2 | Sequential changes of the biomarkers before the development of thrombosis. Each graph indicated the sequential change of individual biomarkers until the day of thrombotic events. The box-whisker plot indicated median and upper/lower quartile of the data of 32 patients complicated with thrombosis.
Of note, thrombotic complications developed even in cases with mild disease severity and not always at the peak of the course of the disease. The incidence of thrombosis decreased over time and might be less frequent in COVID-19 caused by VOC/VOI than the earlier strains, while the concomitant treatments including anticoagulation were different according to the in-hospitalized period.

We have identified that elevated D-dimer and ferritin levels on admission are independent risk factors for the development of thrombosis in COVID-19 patients by multivariate analysis. Several reports have revealed that disease severity and the elevation of D-dimer levels is a predictive factor of thrombosis (23–25). While ferritin was assumingly one of the predictive factors of developing acute respiratory distress syndrome of COVID-19 (28–30), we demonstrated for the first time that the elevation of ferritin was also an independent risk factor of thrombosis in the Japanese population with COVID-19. Since ferritin is induced with various inflammatory mediators including TNF, IL-1, IL-6, and IL-18, the elevation of ferritin level is a surrogate marker in macrophage activation in various diseases (31, 32). Various inflammatory mediators are released during the disease progression in COVID-19, where the innate immune activation is presumably the underlying mechanism of thrombosis, namely immunothrombosis (10, 33). Accordingly, we recommend evaluating ferritin levels as a biomarker of immunothrombosis for the management of patients with COVID-19.

Our findings were consistent with previous multicenter questionnaire surveys in Japan (17) and a recent report from Singapore (34). Accordingly, relatively higher incidences of arterial thrombosis might be a unique feature in the Asian population, but ethnic differences were minimum with respect to venous thrombosis (35). Consistent with the previous reports, thrombotic complications were developed more frequently in patients with severe respiratory disease than the others. These findings would be associated with more severe clinical conditions of patients with thrombosis than those without thrombosis. Although the causal relation was unproven, the association between the epidemic of COVID-19 infection and the increase of out-of-hospital death due to cardiac disease or pulmonary thrombosis were reported, suggesting the possibility that venous or arterial thrombosis is one of the causes of sudden death observed in COVID-19 (36–38). Given the favorable outcomes that prophylactic anticoagulation reduced mortality in the initial observational study (39), guidelines from multiple organizations recommended consistently that hospitalized patients should receive prophylactic dose of anticoagulation therapy (40–42). Nevertheless, the incidence of thrombotic complications was still high in the critically ill patients with COVID-19, even though all patients received standard-dose thromboprophylaxis (5). Additionally, our results suggested that optimal prophylactic treatment needs to be established for the prevention of arterial thrombosis. So far, no preventive effects of aspirin against arterial thrombosis have been demonstrated according to some meta-analyses (43, 44). While the optimization of anticoagulation therapy has been eagerly examined (45–47), concomitant treatment targeting immune activation would be beneficial (48, 49) not only for the pulmonary disease of the patients but also for the prevention of thrombosis (33). Further investigations to identify high-risk patients and to develop effective
TABLE 5 | Comparison of the clinical characteristics of COVID-19 caused by SARS-CoV-2 VOC/VOI or non-VOC/VOI.

|                         | SARS-CoV-2 VOC/VOI, n (%) | SARS-CoV-2 non-VOC/VOI, N = 364 | p-value |
|-------------------------|----------------------------|--------------------------------|---------|
| **Baseline characteristics** |                            |                                |         |
| Age, mean (SD)          | 53 (15.9)                  | 59.5 (17.4)                    | 0.001   |
| ≥65 years, n (%)        | 38 (25%)                   | 160 (44%)                      | <0.001  |
| Male gender, n (%)      | 110 (72%)                  | 248 (68%)                      | 0.34    |
| Body mass index (kg/m²), mean (SD) | 24 (4.7) | 24.5 (5.0) | 0.32 |
| ≥30 kg/m², n (%)        | 16 (11%)                   | 37 (11%)                       | 0.88    |
| Current smoker, n (%)   | 31 (21%)                   | 56 (18%)                       | 0.45    |
| **Severity on admission, n (%)** |                        |                                |         |
| Mild                    | 83 (55%)                   | 196 (54%)                      | 0.87    |
| Moderate                | 39 (26%)                   | 89 (25%)                       |         |
| Severe                  | 30 (20%)                   | 79 (22%)                       |         |
| **Comorbidities**       |                            |                                |         |
| Diabetes mellitus, n (%)| 33 (22%)                   | 79 (22%)                       | 1.00    |
| Hypertension, n (%)     | 48 (32%)                   | 125 (34%)                      | 0.58    |
| Hyperlipidemia, n (%)   | 28 (18%)                   | 54 (15%)                       | 0.31    |
| COPD, n (%)             | 4 (2.6%)                   | 10 (2.7%)                      | 1.00    |
| Asthma, n (%)           | 15 (11%)                   | 22 (6.2%)                      | 0.055   |
| Chronic kidney disease, n (%) | 38 (25%) | 111 (31%) | 0.21 |
| History of coronary artery disease, n (%) | 6 (4.0%) | 13 (3.6%) | 0.83 |
| History of cerebral infarction, n (%) | 6 (4.0%) | 16 (4.9%) | 0.63 |
| History of malignancy, n (%) | 14 (9.3%) | 56 (15%) | 0.07 |
| Active malignancy, n (%) | 5 (3.3%)                   | 9 (2.5%)                       | 0.56    |
| Autoimmune disease, n (%) | 7 (4.6%)                   | 23 (6.3%)                      | 0.46    |
| **Laboratory data at admission** |                         |                                |         |
| White blood cell count (×10⁹/µL), median (IQR) | 5.2 (3.9–7.3) | 5.6 (4.1–7.3) | 0.24 |
| Lymphocyte count (µL), median (IQR) | 927 (630–1,188) | 998 (672–1,387) | 0.02 |
| Hemoglobin (g/dL), median (IQR) | 14.3 (13.1–15.6) | 14.2 (12.7–15.4) | 0.17 |
| Platelet count (×10⁹/µL), median (IQR) | 17.6 (14.9–21.7) | 19.9 (16.3–25.3) | <0.001 |
| CRP (mg/dL), median (IQR) | 3.41 (1.13–8.01) | 4.23 (0.79–9.98) | 0.35 |
| LDH (U/L), median (IQR) | 305 (229–424) | 285 (212–391) | 0.19 |
| Ferritin (ng/mL), median (IQR) | 493 (198–1,073) | 427 (213–828) | 0.28 |
| Creatinine (mg/dL), median (IQR) | 0.84 (0.66–1.01) | 0.84 (0.65–1.03) | 0.78 |
| PT (second), median (IQR) | 10.9 (10.1–11.6) | 11.2 (10.5–12.1) | <0.001 |
| APTT (second), median (IQR) | 32.7 (29.8–36.3) | 31.9 (29.1–35.0) | 0.14 |
| D-dimer (µg/mL), median (IQR) | 0.59 (0.50–1.27) | 0.78 (0.50–1.69) | 0.83 |
| Fibrinogen (mg/dL), median (IQR) | 465 (389–546) | 485 (373–578) | 0.44 |
| FDP (µg/mL), median (IQR) | 2.5 (2.5–3.5) | 4.2 (2.6–6.1) | <0.001 |
| **Treatment**            |                            |                                |         |
| DOAC, n (%)             | 8 (5.3%)                   | 18 (4.9%)                      | 0.88    |
| Prophylactic doses of anticoagulation therapy, n (%) | 43 (28%) | 88 (24%) | 0.33 |
| Therapeutic doses of anticoagulation therapy, n (%) | 29 (19%) | 24 (6.6%) | <0.001 |
| **Outcome, n (%)**      |                            |                                |         |
| Thrombosis, n (%)       | 2 (1.3%)                   | 30 (8.2%)                      | 0.003   |
| Major bleeding, n (%)   | 4 (2.6%)                   | 11 (3.0%)                      | 1.00    |
| Death, n (%)            | 9 (5.9%)                   | 28 (7.7%)                      | 0.48    |

Statistically significant p < 0.05 values are in bold. VOC, variant of concern; VOI, variant of interest; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; LDH, lactate dehydrogenase; PT, prothrombin time; APTT, activated partial thromboplastin time; FDP, fibrinogen degradation products; DOAC, direct oral anticoagulant.
Coagulation abnormality is one of the predictive factors for poor prognosis in COVID-19. Many reports indicated the dysregulation of coagulation systems in fatal cases, and coagulation abnormalities exacerbated the progression of the disease. The elevation of D-dimer on admission was reported in several studies, suggesting that an abnormal activation of the coagulation system had already occurred in the early phase of COVID-19. Several recent reports have suggested pathological functions of vascular endothelial dysfunction in the thrombosis of COVID-19 (49, 50). The complication of floating thrombi in the ascending aorta and pulmonary thromboembolism without DVT are known as characteristic patterns of thrombosis observed in COVID-19 (27). Similar findings were also observed in our study. After the infection of type II pneumocytes by SARS-CoV-2, cytokine production and neutrophil extracellular traps from migrated neutrophils might induce the activation of vascular endothelial cells, which results in immunothrombosis. Although D-dimer levels remained within the normal range in patients post COVID-19, the levels of factor VIII and PAI-1 were elevated after 4 months (51), suggesting the continuous activation of the vascular endothelium. Although SARS-CoV-2 had been considered to infect vascular endothelial cells in the early report (52), such direct infection is now considered a rare condition (53–55).

At the beginning of the observation period, all infected patients were required to be hospitalized regardless of their disease severity in Japan. Therefore, our data included a relatively high percentage of less severe patients. Such circumstances enabled us to assess the natural course of the disease and resultant complications during the early phase of the COVID-19. Our study revealed that thrombosis could occur in patients who did not require oxygen therapy, which would contribute to updating the management of cases with mild disease severity, including outpatient checkups at non-medical institutions. According to our findings, we propose to measure D-dimer and ferritin levels on admission to identify high-risk patients and follow-up these parameters in such patients. A decreased incidence of thrombosis was observed during a later period in our cohort. The results might reflect the differences in clinical characteristics among the SARS-CoV-2 strains and/or the increasing use of anticoagulation therapeutics. So far, no study has identified the incidence of thrombosis among patients infected with different SARS-CoV-2 strains. Recently, several reports described the promotion of thrombus formation via the activation of platelets (56), the induction of tissue factor (57), or PAI-1 (58) using virus particle of the Wuhan strain or recombinant S1 protein with D614G single mutation. Although the mutations carried by VOC/VOI might reduce its thrombogenic properties instead of the increased ACE2 binding affinity and the enhanced infectivity, it would be difficult to identify the reason for the decreased incidence of thrombosis from our observation. To clarify the property of the thrombogenic potential among different SARS-CoV-2 strain, further data accumulation is required.

We must admit several limitations in this study. Due to the retrospective nature of the study, the issue of residual confounding was unavoidable. The incidence of thrombosis may have been underestimated since not all cases underwent ultrasound or contrast CT as a screening. The history of venous thrombosis would be a risk factor for developing another thrombosis. However, few patients had a history of venous thrombosis in our study, indicating that we might not collect several medical histories appropriately. Since the therapeutic anticoagulation therapy might be beneficial in the high-risk patients of thrombosis, we could not associate the superiority of the therapeutic approach to the prophylactic approach because of the nature of the study. To minimize the selection bias, we analyzed all hospitalized patients consecutively. However, there are missing data about some biomarkers or follow-up data, and the data of patients transferred to another institute whose systemic condition was not fully recovered. Furthermore, our multivariate logistic regression model may be overloaded with respect to the number of independent variables due to the small sample size. These limitations restricted the generalizability of our observations.

In conclusion, we reported the detailed clinical characteristics of COVID-19 patients, including variants information, with a focus on the development of thrombosis. Further large-scale studies to identify high-risk populations and establish appropriate preventive and therapeutic interventions would be required in the management of thrombotic complications in COVID-19.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

This study protocol was approved by the Ethics Committees of Tokyo Medical and Dental University (TMDU). Reference ID was M2020-027. Written informed consent was not required for this study, in accordance with the local legislation and institutional requirements.

AUTHOR CONTRIBUTIONS

SY, TH, TM, TO, TT, and YMa designed the research. SO, TH, MA, DK, TM, TA, SS, TT, HT, YT, KT, STo, and AH analyzed the data. SO, TH, AE, and SY wrote the manuscript. YMi and SY supervised the manuscript. All authors contributed to the data collection.

FUNDING

This work was supported by Japan Agency for Medical Research and Development (AMED) under grant number 21ek0410083h0002.
ACKNOWLEDGMENTS

We would like to thank all the participants in our institute for the management of patients with COVID-19, Asuka Matsufuji for the data collection, and Lucinda Beck for the careful proofreading of the manuscript.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcvm.2021.767074/full#supplementary-material

Supplementary Figure 1 | Floating thrombus in aortic arch. Single-phase contrast-enhanced CT shows a filling defect in the aortic arch (arrowhead).

REFERENCES

1. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. (2020) 130:2620–9. doi: 10.1172/JCI137244

2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. (2020) 395:1054–62. doi: 10.1016/S0140-6736(20)30566-3

3. Santoliquido A, Porfidia A, Nesi A, Matteis G De, Marrone G, Porceddu E, et al. Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmaceutical thromboprophylaxis. J Thromb Haemost. (2020) 18:2358–63. doi: 10.1111/jth.14992

4. Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost. (2020) 4:e1178–91. doi: 10.1002/rth.12439

5. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers RCMA, Drijver YB, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. (2020) 191:145–7. doi: 10.1016/j.thromres.2020.04.013

6. Dalager-Pedersen M, Lund LC, Mariager T, Winther R, Hellfritsch M, Larsen TB, et al. Venous thromboembolism and major bleeding in patients with coronavirus disease 2019 (COVID-19): a nationwide, population-based cohort study. Clin Infect Dis. (2021) 6:cbi080. doi: 10.1093/cid/cbi080

7. Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. (2020) 46:1089–98. doi: 10.1007/s00134-020-00602-x

8. O’Sullivan JM, Gonagle DM, Ward SE, Preston RJS, O’Donnell JS. Endothelial cells orchestrate COVID-19 coagulopathy. Lancet Haematol. (2020) 7:e553–5. doi: 10.1016/S2352-3026(20)30215-5

9. Libby P, Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur Heart J. (2020) 41:3038–44. doi: 10.1093/eurheartj/ehaa623

10. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. (2020) 142:1176–89. doi: 10.1161/CIRCULATIONAHA.120.048488

11. Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. J Intensive Care. (2020) 8:1–11. doi: 10.1186/s40560-020-00466-z

12. Dhont S, Derom E, Van Braeckel E, Depuydt P, Lambrecht BN. Conceptions of the pathophysiology of happy hypoxemia in COVID-19. Respir Res. (2021) 22:1–9. doi: 10.1186/s12931-021-01614-1

13. O’Toole Á, Scher E, Underwood A, Jackson B, Hill V, McCrone JT, et al. Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool. Virus Evol. (2021) 7:vbea064. doi: 10.1093/ve/vbea064

14. World Health Organization. Tracking SARS-CoV-2 Variants. Available online at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed August 30, 2021).

15. Yamashita Y, Hara N, Obana M, Ikeda S, Furuuchi M, Ishiguro S, et al. Clinical features of venous thromboembolism in patients with coronavirus disease 2019 (COVID-19) in Japan: a case series study. Circ J. (2021) 85:309–13. doi: 10.1253/circj-cj-20-1302

16. Yamashita Y, Maruyama Y, Satokawa H, Nishimoto Y, Tsujino I, Sakashita H, et al. Incidence and clinical features of venous thromboembolism in hospitalized patients with coronavirus disease 2019 (COVID-19) in Japan. Circ J. (2021). doi: 10.1253/circj-cj-21-0169

17. Horiiuchi H, Morishita E, Urano T, Yokoyama K. COVID-19-related thrombosis in Japan: final report of a questionnaire-based survey in 2020. J Atheroscler Thromb. (2021) 28:606–16. doi: 10.5551/japt.BP07001

18. Fujisawa N, Nakajima M, Kaszynski RH, Fukushima K, Tanaka M, Yajima K, et al. Prevalence of thromboembolic events and status of prophylactic anticoagulant therapy in hospitalized patients with COVID-19 in Japan. J Infect Chemother. (2021) 27:869–75. doi: 10.1016/j.jiac.2021.02.019

19. Nagano K, Tani-Sassa C, Iwasaki Y, Takatsuki Y, Yuasa S, Takahashi Y, et al. SARS-CoV-2 R1 lineage variants that prevailed in Tokyo in March 2021. J Med Virol. (2021) 93:683–6. doi: 10.1002/jmv.25790

20. Shirato K, Nao N, Katano H, Takayama I, Saito S, Kato F, et al. Diagnostic methods for detection for novel coronavirus 2019nCoV-2019 in Japan. Jpn J Infect Dis. (2020) 73:304–7. doi: 10.7883/yoken.JJID.2020.061

21. Japanese ministry of Health, Labour and Welfare. Guide of the Medical Treatment of the Noble Coronavirus. 5th edn. Available online at: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00111.html (accessed August 30, 2021).

22. Schulman S, Angerà U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antithrombotic medicinal products in surgical patients. J Thromb Haemost. (2010) 8:202–4. doi: 10.1111/j.1538-7836.2009.03678.x

23. Zhang L, Feng X, Zhang D, Jiang C, Mei H, Wang J, et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China. Circulation. (2020) 142:114–28. doi: 10.1161/CIRCULATIONAHA.120.046702

24. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. (2020) 18:1421–4. doi: 10.1111/jth.14830
25. Artifoni M, Danic G, Gautier G, Gicquel P, Boutolle D, Raffi F, et al. Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictor factors. J Thromb Thrombolysis. (2020) 50:1:211–6. doi: 10.1007/s11239-020-02146-0

26. Raphankiewicz A V, Mai X, Carsons SE, Pittaluga S, Kleiner DE, Berger JS, et al. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series. EClinicalMedicine. (2020) 24:1000434. doi: 10.1016/j.eclinm.2020.1000434

27. Cheruiyot I, Kipkorir V, Ngure B, Misiani M, Munguti J, Ogeng’o J. Arterial thrombosis in coronavirus disease 2019 patients: a rapid systematic review. Anavasc Surg. (2021) 70:273–81. doi: 10.1016/j.avsg.2020.08.086

28. Lin Z, Long F, Yang Y, Chen X, Xu L, Yang M. Serum ferritin as an independent risk factor for severity in COVID-19 patients. J Infect. (2020) 81:647–79. doi: 10.1016/j.jinf.2020.06.053

29. Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int J Infect Dis. (2020) 96:467. doi: 10.1016/j.ijid.2020.05.055

30. Chaudhary R, Garg J, Houghton DE, Murad MH, Kondur A, Chaudhary R, et al. Thromboinflammatory biomarkers in COVID-19: systematic review and meta-analysis of 17,052 patients. EClinicalMedicine. (2020) 2:355. doi: 10.1016/j.eclinm.2020.100290

31. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets of COVID-19. Nat Rev Rheumatol. (2020) 16:103–18. doi: 10.1038/s41584-019-00888-x

32. Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. (2019) 10:119. doi: 10.3389/fimmu.2020.00119

33. McGonagle D, Ramanan A V, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat Rev Rheumatol. (2021) 17:145–57. doi: 10.1038/s41584-020-00571-1

34. Tan CW, Fan BE, Teo WZY, Tung ML, Shafi H, Christopher D, et al. Low expression of endothelial plasminogen activator inhibitor-1. Eur J Heart Fail. (2021) 23:330–6. doi: 10.1002/ejhf.1916

35. Iba T, Connors JM, Spyropoulos AC, Wada H, Levy JH. Ethnic distributions of SARS-CoV-2 seroconversion and out-of-hospital sudden cardiac arrest. Eur J Heart Fail. (2021) 23:388. doi: 10.1002/ejhf.1934

36. Coleman KM, Saleh M, Mountantonakis SE. Association between regional distributions of SARS-CoV-2 seroscreening and out-of-hospital sudden death during the first epidemic outbreak in New York. Hear Research. (2021) 395:1–8. doi: 10.1016/j.heares.2020.11.022

37. Benedetti GD, Burnett A, Allen A, Blumenstein M, Clark ND, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis. (2020) 50:72–81. doi: 10.1007/s11239-020-02138-z

38. Baldi E, Sechi GM, Mahe C, Canevari F, Brancaglione A, Primi R, et al. COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests. Eur Heart J. (2020) 41:3045–54. doi: 10.1093/eurheartj/ehaa508

39. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. (2020) 76:1224–4. doi: 10.1016/j.jacc.2020.05.001

40. Cuker A, Tseng EK, Nieuwlaat R, Angchaisukiri P, Blair C, Dan E, et al. American society of hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. (2021) 5:872–88. doi: 10.1182/bloodadvances.2020003763

41. Baldi E, Sechi GM, Mahe C, Canevari F, Brancaglione A, Primi R, et al. COVID-19: a multifaceted viral vasculopathy syndrome. Ann Diag Pathol. (2021) 50:151645. doi: 10.1016/j.anndiagpath.2020.151645

42. National Institutes of Health. COVID-19 Treatment Guidelines. Available online at: https://www.covid19treatmentguidelines.nih.gov/about-the-guidelines/whats-new/ (accessed August 30, 2021).
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.